Bio Impact Capital LLC Trevi Therapeutics, Inc. Transaction History
Bio Impact Capital LLC
- $611 Million
- Q1 2024
A detailed history of Bio Impact Capital LLC transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Bio Impact Capital LLC holds 1,340,960 shares of TRVI stock, worth $3.58 Million. This represents 0.76% of its overall portfolio holdings.
Number of Shares
1,340,960Holding current value
$3.58 Million% of portfolio
0.76%Shares
1 transactions
Others Institutions Holding TRVI
# of Institutions
79Shares Held
50.5MCall Options Held
2.2KPut Options Held
600-
Nea Management Company, LLC Timonium, MD11.4MShares$30.4 Million2.75% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA7.38MShares$19.7 Million1.34% of portfolio
-
Rubric Capital Management LP New York, NY5.56MShares$14.9 Million0.65% of portfolio
-
Viking Global Investors LP4.4MShares$11.7 Million0.06% of portfolio
-
Vr Adviser, LLC New York, NY3.42MShares$9.14 Million1.01% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $156M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...